PMID- 36284634
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221028
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2022
DP  - 2022
TI  - Overexpression of Laminin 5gamma2 Chain Correlates with Tumor Cell Proliferation, 
      Invasion, and Poor Prognosis in Laryngeal Squamous Cell Carcinoma.
PG  - 7248064
LID - 10.1155/2022/7248064 [doi]
LID - 7248064
AB  - OBJECTIVE: Laryngeal squamous cell carcinoma (LSCC) is a common malignant tumor. 
      Laminin 5gamma2 chain (LAMC2) was reported to be associated with tumorigenesis. This 
      study explored the role of LAMC2 on LSCC progression by regulating the 
      integrinbeta1/FAK/Src/AKT pathway. METHODS: The level of LAMC2 in 46 LSCC patients 
      was detected by qRT-PCR and western blot. Then the relationship between LAMC2 
      expression and LSCC malignancy as well as prognosis was analyzed, and the effect 
      of LAMC2 expression on LSCC patient survival was also analyzed using the 
      Kaplan-Meier survival curves. Afterwards, the LSCC cells were transfected with 
      LAMC2 overexpression and knockdown vectors, the effect of LAMC2 on LSCC cell 
      viability, proliferation ability, cell cycle, cell migration, and invasion were 
      detected by CCK-8, colony formation, flow cytometry, wound healing, and Transwell 
      assays. The expression of EMT-related biomarkers and integrin beta1/FAK/Src/AKT 
      signaling-related proteins was detected by western blot. Moreover, the effect of 
      LAMC2 on LSCC tumor growth was evaluated by in vivo xenograft experiments and 
      western blot. RESULTS: LAMC2 was expressed at high level in LSCC tissues and 
      associated with poor prognosis. LAMC2 overexpression increased TU177 cell 
      viability, proliferation ability, promoted cell cycle, cell migration, and 
      invasion capacity. The expression of N-cadherin, vimentin, and 
      integrinbeta1/FAK/Src/AKT related proteins was increased, while the expression of 
      E-cadherin protein was decreased. When the LAMC2 knockdown in AMC-HN-8 cells had 
      opposite effects. Furthermore, shLAMC2 decreased tumor volume and the expression 
      of LAMC2, Ki-67 and integrinbeta1, but increased the expression of E-cadherin in 
      LSCC tumor-bearing mice. CONCLUSION: The findings suggested that LAMC2 was 
      overexpressed in LSCC and correlated with poor prognosis. LAMC2 knockdown 
      inhibited LSCC progression by regulating the integrinbeta1/FAK/Src/AKT signaling 
      pathway. Therefore, LAMC2 could be a target for LSCC therapy.
CI  - Copyright (c) 2022 Chengyi Yin et al.
FAU - Yin, Chengyi
AU  - Yin C
AUID- ORCID: 0000-0002-1461-4244
AD  - Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, 
      The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
FAU - Ma, Bingliang
AU  - Ma B
AD  - Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, 
      The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
FAU - Zhang, Xilin
AU  - Zhang X
AD  - Research Department, The First Affiliated Hospital, Huzhou University, The First 
      People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
FAU - Lan, Longjiang
AU  - Lan L
AD  - Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, 
      The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
FAU - Ren, Gang
AU  - Ren G
AD  - Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, 
      The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
FAU - Xu, Jue
AU  - Xu J
AD  - Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, 
      The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
FAU - Wang, Jianqiu
AU  - Wang J
AUID- ORCID: 0000-0003-0501-7410
AD  - Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, 
      The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
LA  - eng
PT  - Journal Article
DEP - 20221015
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC9588344
COIS- The authors declare that they have no conflicts of interest..
EDAT- 2022/10/27 06:00
MHDA- 2022/10/27 06:01
PMCR- 2022/10/15
CRDT- 2022/10/26 02:06
PHST- 2022/08/17 00:00 [received]
PHST- 2022/09/24 00:00 [accepted]
PHST- 2022/10/26 02:06 [entrez]
PHST- 2022/10/27 06:00 [pubmed]
PHST- 2022/10/27 06:01 [medline]
PHST- 2022/10/15 00:00 [pmc-release]
AID - 10.1155/2022/7248064 [doi]
PST - epublish
SO  - J Oncol. 2022 Oct 15;2022:7248064. doi: 10.1155/2022/7248064. eCollection 2022.